Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results

Results from the main parts (24 weeks) of 2 concizumab phase 2 trials are presented: explorer4 in hemophilia A (HA) or B (HB) with inhibitors (HAwI/HBwI) and explorer5 in HA. The trials aimed to evaluate the efficacy of daily subcutaneous concizumab prophylaxis (evaluated as annualized bleeding rate...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Shapiro, Amy D., Angchaisuksiri, Pantep, Astermark, Jan, Benson, Gary, Castaman, Giancarlo, Chowdary, Pratima, Eichler, Hermann, Jiménez-Yuste, Victor, Kavakli, Kaan, Matsushita, Tadashi, Poulsen, Lone Hvitfeldt, Wheeler, Allison P., Young, Guy, Zupancic-Salek, Silva, Oldenburg, Johannes
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Thrombosis and Hemostasis
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6895373/
https://ncbi.nlm.nih.gov/pubmed/31444162
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019001542
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados